GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) recently updated its clinical study on the safety, efficacy, and immune response of a sequential treatment for Chronic Hepatitis B (CHB). Officially titled ‘A Phase 2, Single-blinded, Randomised, Controlled Multi-country Study,’ the research aims to evaluate the benefits of combining an anti-sense oligonucleotide (ASO) and targeted immunotherapy (CHB-TI) in CHB patients already receiving nucleos(t)ide analogue (NA) therapy. This study is significant as it seeks to enhance treatment efficacy for CHB, a persistent global health issue.
The interventions being tested include GSK3228836, an ASO drug, and GSK3528869A, a biological CHB-targeted immunotherapy. GSK3228836 is administered subcutaneously, while GSK3528869A is given intramuscularly. The goal is to determine the added value of sequential therapy over GSK3228836 alone.
The study follows a randomized, sequential intervention model with single masking for participants. It primarily focuses on treatment outcomes, with an open-label approach for the first treatment and single-blinded for the second.
Key study dates include its start on February 14, 2022, with the primary completion and estimated study completion yet to be specified. The last update was submitted on October 13, 2025, indicating ongoing progress.
This update could potentially influence GSK’s stock performance positively by showcasing its commitment to advancing CHB treatment. It may also affect investor sentiment, especially if the results demonstrate significant efficacy improvements. Competitors in the hepatitis treatment market will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.